Clinical manifestation and molecular genetic characterization of MYH9 disorders
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
19557653
DOI
10.1080/09537100902993022
PII: 912718562
Knihovny.cz E-zdroje
- MeSH
- buněčná inkluze MeSH
- exony MeSH
- genetické nemoci vrozené krev genetika patologie MeSH
- glykoproteiny MeSH
- granulocyty patologie MeSH
- lidé MeSH
- molekulární motory genetika MeSH
- mutace MeSH
- mutační analýza DNA MeSH
- polymerázová řetězová reakce MeSH
- rodina MeSH
- syndrom MeSH
- těžké řetězce myosinu genetika MeSH
- trombocytopenie MeSH
- trombocyty patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- glykoproteiny MeSH
- molekulární motory MeSH
- MYH9 protein, human MeSH Prohlížeč
- těžké řetězce myosinu MeSH
Currently, the May-Hegglin anomaly (MHA), Sebastian (SBS), Fechtner (FTNS) and Epstein (EPS) syndrome are considered to be distinct clinical manifestations of a single disease caused by mutations of the MYH9 gene encoding the heavy chain of non-muscle myosin IIA (NMMHC-IIA). Manifestations of these disorders include giant platelets, thrombocytopenia and combinations of the presence of granulocyte inclusions, deafness, cataracts and renal failure. We examined 15 patients from 10 unrelated families on whom we performed immunostaining of NMMHC-IIA in blood samples. Polymerase chain reaction (PCR) analysis of selected exons of the MYH9 gene revealed mutations in nine samples with one novel mutation. Results of fluorescence and mutational analysis were compared with clinical manifestations of the MYH9 disorder. We also determined the number of glycoprotein sites on the surface of platelets. Most patients had an increased number of glycoproteins, which could be due to platelet size.
Citace poskytuje Crossref.org